3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
Specimen Handling
186
pembrolizumab
151
Magnetic Resonance Spectroscopy
151
Carboplatin
114
Biopsy
104
Cyclophosphamide
96
Cisplatin
88
Paclitaxel
79
Gemcitabine
71
Bevacizumab
68
fludarabine
60
Nivolumab
58
Fluorouracil
51
Radiotherapy
49
Dexamethasone
47
Capecitabine
47
Pemetrexed
46
Oxaliplatin
44
Docetaxel
44
Rituximab
43
Leucovorin
41
Doxorubicin
40
venetoclax
39
durvalumab
39
atezolizumab
39
Temozolomide
32
Standard of Care
32
Radiation
32
Cetuximab
32
130-nm albumin-bound paclitaxel
32
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
SGN-LIV1A
×
30 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled